Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 5, 2025Hematology

Tailored treatment of acute immune-mediated thrombotic thrombocytopenic purpura

View Full Paper
Ask AI
Bookmark
Share

Authors

PBPaul BrinkkötterUniversity of Cologne

Discussion

Loading...

Member takes

Implication

Observational analysis shows improved outcomes with anti-VWF therapy in iTTP patients, suggesting earlier treatment helps reduce thrombotic complications.

Key Points

  • Early diagnosis and treatment may enable a TPE-free approach in managing iTTP.
  • Anti-VWF therapy with caplacizumab has improved outcomes in treating thrombotic microangiopathy.
  • Therapeutic plasma exchange remains a key component of standard care alongside glucocorticoids.
  • Guidelines recommend close monitoring and individualized treatment strategies based on ADAMTS13 levels.

Cite This Study

Paul Brinkkötter (2025) studied this question.

synapsesocial.com/papers/6940224e2d562116f28fc11chttps://doi.org/10.1182/hematology.2025000757
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange2024 · 37 citations
  2. 2Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP2024 · 16 citations
  3. 3A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura2024 · 9 citations
  4. 4Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)2025 · 52 citations
  5. 5Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis2019 · 88 citations